Faropair CV 300 Tablet contains Faropenem 300 mg and Clavulanic Acid 125 mg, a dual-action beta-lactam antibiotic combination designed to target susceptible and beta-lactamase–producing bacteria. Faropenem provides broad-spectrum carbapenem activity, while Clavulanic Acid inhibits beta-lactamase enzymes, enhancing overall antibacterial efficacy.
Clinically, this combination is indicated for respiratory tract infections, urinary tract infections, skin and soft tissue infections, and other mixed bacterial infections. It is particularly effective in treating infections caused by resistant pathogens where standard beta-lactams may fail.
The tablet formulation ensures consistent bioavailability, accurate dosing, and reliable therapeutic outcomes, making it suitable for hospitals, clinics, infectious disease centers, and retail pharmacies. Oral administration enhances patient compliance and convenience.
Faropair CV 300 Tablet helps in rapid symptom resolution, prevention of recurrence, and effective management of resistant bacterial infections. Its evidence-based combination makes it a trusted antibiotic option for healthcare providers managing complex infections under medical supervision.